generative-chemistry
(3)
Insilico Medicine taught AI to design a drug. Now comes the human test.
A lung disease, an unfamiliar target and a molecule designed by machines: Insilico Medicine has taken its AI discovery experiment into Phase III. The clever part is how it pays for the long wait.
Inductive Bio
Inductive Bio is a New York-based AI company building a machine learning platform that predicts how small-molecule drugs will behave in the body before they are ever synthesized. By training models on a pre-competitive data consortium shared across biopharma teams, its Beacon models, Compass software, and Indy chemistry assistant help medicinal chemists nominate better development candidates faster - reducing the costly 'whack-a-mole' of balancing potency against ADMET properties in preclinical drug discovery.
Josh Haimson
Josh Haimson is the co-founder and CEO of Inductive Bio, a New York based AI company building software to speed up small molecule drug discovery. Before starting Inductive in 2024 with Ben Birnbaum, Josh ran product for the machine learning and data curation teams at Flatiron Health, generating real-world evidence across a network of more than 2 million cancer patients. The company raised a $25M Series A in May 2025 led by Obvious Ventures, and its Compass platform helps chemists predict a molecule's ADMET properties before it is ever synthesized, attacking the 'whack-a-mole' bottleneck that slows drug development.